drug_type
RELEVANT_DRUG
intervention_type
Autologous cellular therapy (CAR T cells)
drug_description
Autologous, genetically engineered anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy; single IV infusion designed to deplete CD19+/CD20+ B cells to treat refractory autoimmune diseases.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a dual-target chimeric antigen receptor recognizing CD19 and CD20 on B cells. Upon antigen engagement, the CAR T cells become activated and mediate cytotoxic killing of CD19+/CD20+ B-lineage cells, leading to B-cell depletion and suppression of autoantibody-driven immune responses.
drug_name
IMPT-514
nct_id_drug_ref
NCT06462144